Biblio Discovery — Demo Discovery Service

37 hasil untuk "Subhashis Banerjee"

Menampilkan 1–20 · 3,04 detik · RSS

  1. Artikel Jurnal

    Novel Volumetric Sub-region Segmentation in Brain Tumors

    Subhashis Banerjee; Sushmita Mitra

    Frontiers in Computational Neuroscience, Vol. 14 · 2020 · Inggris · DOAJ Scopus

    A novel deep learning based model called Multi-Planar Spatial Convolutional Neural Network (MPS-CNN) is proposed for effective, automated segmentation of different sub-regions viz. peritumoral edema (ED), necrotic core (NCR), enhancing and non-enhancing tumor core (ET/NET), from multi-modal MR…

  2. Artikel Jurnal Teks lengkap

    Volumetric brain tumour detection from MRI using visual saliency

    Somosmita Mitra; Subhashis Banerjee; Yoichi Hayashi

    PLOS ONE, Vol. 12 No. 11 · 2017 · Inggris · PLOS Scopus

    Medical image processing has become a major player in the world of automatic tumour region detection and is tantamount to the incipient stages of computer aided design. Saliency detection is a crucial application of medical image processing, and serves in its potential aid to medical practitioners…

    Juga tersedia di: DOAJ

  3. Artikel Jurnal

    Iris Segmentation Using Interactive Deep Learning

    Mousumi Sardar; Subhashis Banerjee; Sushmita Mitra

    IEEE Access, Vol. 8 · 2020 · Inggris · DOAJ Scopus

    Automated iris segmentation is an important component of biometric identification. The role of artificial intelligence, particularly machine learning and deep learning, has been considerable in such automated delineation strategies. Although the use of deep learning is a promising approach in…

  4. Artikel Jurnal Teks lengkap

    Regulation of Expression of Citrate Synthase by the Retinoic Acid Receptor-Related Orphan Receptor α (RORα)

    Christine Crumbley; Yongjun Wang; Subhashis Banerjee dkk.

    PLoS ONE, Vol. 7 No. 4 · 2012 · Inggris · PLOS Scopus

    The retinoic acid receptor-related orphan receptor α (RORα) is a member of the nuclear receptor superfamily of transcription factors that plays an important role in regulation of the circadian rhythm and metabolism. Mice lacking a functional RORα display a range of metabolic abnormalities including…

    Juga tersedia di: DOAJ

  5. Artikel Jurnal Teks lengkap

    A Novel GBM Saliency Detection Model Using Multi-Channel MRI

    Subhashis Banerjee; Sushmita Mitra; B. Uma Shankar dkk.

    PLOS ONE, Vol. 11 No. 1 · 2016 · Inggris · PLOS Scopus

    The automatic computerized detection of regions of interest (ROI) is an important step in the process of medical image processing and analysis. The reasons are many, and include an increasing amount of available medical imaging data, existence of inter-observer and inter-scanner variability, and to…

    Juga tersedia di: DOAJ

  6. Artikel Jurnal

    Reproducibility and Explainability of Deep Learning in Mammography: A Systematic Review of Literature

    Deeksha Bhalla; Krithika Rangarajan; Tany Chandra dkk.

    Indian Journal of Radiology and Imaging, Vol. 34 No. 03 · 2024 · Inggris · DOAJ Scopus

    Background Although abundant literature is currently available on the use of deep learning for breast cancer detection in mammography, the quality of such literature is widely variable.

  7. Artikel Jurnal Teks lengkap

    Correction: Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression

    Ariadna Amador; Yongjun Wang; Subhashis Banerjee dkk.

    PLOS ONE, Vol. 11 No. 5 · 2016 · Inggris · PLOS Scopus

    [This corrects the article DOI: 10.1371/journal.pone.0151014.].

    Juga tersedia di: DOAJ

  8. Artikel Jurnal Teks lengkap

    Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression

    Ariadna Amador; Yongjun Wang; Subhashis Banerjee dkk.

    PLOS ONE, Vol. 11 No. 3 · 2016 · Inggris · PLOS Scopus

    The nuclear receptors REV-ERBα and REV-ERBβ are transcription factors that play pivotal roles in the regulation of the circadian rhythm and various metabolic processes. The circadian rhythm is an endogenous mechanism, which generates entrainable biological changes that follow a 24-hour period. It…

    Juga tersedia di: DOAJ

  9. Artikel Jurnal

    Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial

    Ian M. Catlett; Lu Gao; Yanhua Hu dkk.

    Dermatology and Therapy, Vol. 14 No. 10 · 2024 · Inggris · DOAJ Scopus

    Abstract Background Psoriasis, a chronic, immune-mediated, inflammatory disease, affects 2‒3% of the population. Tyrosine kinase 2 (TYK2) mediates cytokine signaling involved in adaptive [interleukin (IL)-12, IL-23] and innate (type-I interferons) immune responses; IL-23–driven T-helper (Th)17…

  10. Artikel Jurnal

    Streamlining neuroradiology workflow with AI for improved cerebrovascular structure monitoring

    Subhashis Banerjee; Fredrik Nysjö; Dimitrios Toumpanakis dkk.

    Scientific Reports, Vol. 14 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract Radiological imaging to examine intracranial blood vessels is critical for preoperative planning and postoperative follow-up. Automated segmentation of cerebrovascular anatomy from Time-Of-Flight Magnetic Resonance Angiography (TOF-MRA) can provide radiologists with a more detailed and…

  11. Artikel Jurnal

    Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis

    Atul Deodhar; Miroslawa Nowak; June Y. Ye dkk.

    Rheumatology and Therapy, Vol. 12 No. 5 · 2025 · Inggris · DOAJ Scopus

    Abstract Introduction This study aimed to evaluate the influence of background conventional synthetic disease-modifying antirheumatic drug (csDMARD) use on efficacy and safety of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with…

  12. Artikel Jurnal

    Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

    Vibeke Strand; Evo Alemao; Thomas Lehman dkk.

    Arthritis Research & Therapy, Vol. 20 No. 1 · 2018 · Inggris · DOAJ Scopus

    Abstract Background To explore the effect of abatacept treatment on patient-reported outcomes (PROs) in psoriatic arthritis (PsA). Methods Patients with PsA were randomised (1:1) to subcutaneous abatacept 125 mg weekly/placebo for 24 weeks with early escape (EE) to open-label abatacept (week 16)…

  13. Artikel Jurnal

    Ultra-high resolution, multi-scale, context-aware approach for detection of small cancers on mammography

    Krithika Rangarajan; Aman Gupta; Saptarshi Dasgupta dkk.

    Scientific Reports, Vol. 12 No. 1 · 2022 · Inggris · DOAJ Scopus

    Abstract While detection of malignancies on mammography has received a boost with the use of Convolutional Neural Networks (CNN), detection of cancers of very small size remains challenging. This is however clinically significant as the purpose of mammography is early detection of cancer, making it…

  14. Artikel Jurnal Teks lengkap

    Cannabidiol improves learning and memory deficits and alleviates anxiety in 12-month-old SAMP8 mice

    Monica N. Goodland; Subhashis Banerjee; Michael L. Niehoff dkk.

    PLOS One, Vol. 20 No. 8 · 2025 · Inggris · PLOS Scopus

    Cannabidiol (CBD) has gained a lot of interest in recent years for its purported medicinal properties. CBD has been investigated for the treatment of anxiety, depression, epilepsy, neuroinflammation, and pain. Recently there has been an interest in CBD as a possible treatment for age-related…

  15. Artikel Jurnal

    Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial

    Laurent Arnaud; Marta Mosca; Anca Askanase dkk.

    Lupus Science and Medicine, Vol. 12 No. 1 · 2025 · Inggris · DOAJ Scopus

    Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib 3 mg two times per day dose. Changes in patient-reported outcomes, collected as exploratory…